32
Participants
Start Date
December 13, 2024
Primary Completion Date
December 30, 2025
Study Completion Date
August 30, 2026
TACE
TACE procedure was a 2.8-F microcatheter was super-selectively inserted into the tumor feeding artery using the coaxial technique. Then a combination of lipiodol (5-15 ml), lobaplatin (30-50 mg), and Pirarubicin (30-50 mg) was infused into each tumor. We defined technical success as complete embolization of the tumor-feeding artery resulting in no tumor staining observed by angiogram at the end of procedure.
Lenvatinib
(12 mg (body weight ≥60 kg) , 8 mg (body weight \<60 kg) orally once a day
PD-1 Inhibitors
Tislelizumab (200mg intravenously every 3 weeks), Sintilimab (200mg intravenously every 3 weeks), Camrelizumab (200mg intravenously every 3 weeks)
RECRUITING
Qunfang Zhou, Beijing
Sun Yat-sen University
OTHER